Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors

University of Maryland Baltimore (UMB)

Status

Begins enrollment in 2 months

Conditions

Breast Cancer Survivorship

Obesity and Overweight

Treatments

Other: Broccoli microgreen (BMG)

Study type

Interventional

Funder types

Other

Identifiers

NCT07032545

HP-00113949

Details and patient eligibility

About

Obesity can pose significant challenges to maintaining long-term health in cancer survivors by increasing their risk of cancer coming back. Eating a healthy diet is an important way to help manage weight and improve overall health. Broccoli microgreens (BMG) are young broccoli plants packed with nutrients, and research suggests they may help prevent cancer.

Previous studies in mice showed that BMG can improve gut health and metabolism, leading to better health outcomes in obese animals. This study will test whether BMG can be a useful addition to the diet of obese breast cancer (BC) survivors who have a higher risk of their cancer returning.

24 obese BC survivors will be invited to eat one serving (one cup, ~57 gram) of fresh BMG every day for two weeks. This will help understand if people can stick to this diet, how their bodies respond, and whether it affects metabolism and inflammation-two key factors linked to cancer risk. Biological markers such as body fat, glucose and lipids as well as gut bacterial changes will be analyzed to see how BMG affects individual health.

This study may help create new diet strategies to improve health, reduce cancer risk, and support long-term recovery in cancer patients who are overweight or obese. In the future, this research could help doctors personalize nutrition plans to better support cancer survivors.

Full description

In this pilot clinical trial, 24 obese BC survivors from the University of Maryland Medical Center in Baltimore will be recruited to participate in a single-arm 2-week BMG (broccoli microgreen) intervention trial. Several outcomes will be tested, including study feasibility, patient compliance of one serving size of raw BMG and metabolic parameter changes. Biological samples such as blood and fecal samples as well as study questionnaires will be collected at baseline and 2 weeks post-intervention to measure the outcomes. The main hypothesis of this study is that incorporating the proposed BMG quantity into daily meals is feasible in obese BC survivors. The secondary hypothesis is that BMG may improve the metabolic profiles and gut health in obese subjects. This proof-of-concept prospective study will provide important clinical insights into beneficial effects of BMG on mitigating obesity and related metabolic disorders, which strategies may complement traditional survivorship management and support long-term health outcomes for BC survivors.

Enrollment

24 estimated patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

Female
Had a diagnosis of breast cancer (Stage I-III)
2 to 60 months post-curative treatment (surgery, chemotherapy, and/or radiation)
BMI > 30 kg/m² (obese classification)
Willing to avoid cruciferous vegetables during the study
Able to sign an IRB-approved consent form

Exclusion criteria

Have any contraindications to the proposed nutrition intervention as identified by their medical provider, their designee, or the study team (e.g., GI conditions, medication requirements, pregnancy, breastfeeding, recent history of an eating disorder).
Allergy or intolerance to cruciferous vegetables
Currently taking broccoli extract supplements